Article Information
PubMed
Published By
History
- Received March 27, 2013
- Revision received September 9, 2013
- Accepted October 12, 2013
- First published November 27, 2013.
- Version of record published November 27, 2013.
Copyright & Usage
Copyright © 2013 the authors 0270-6474/13/3318712-16$15.00/0
Author Information
- Danielle A. Simmons1,
- Nadia P. Belichenko1,
- Tao Yang1,
- Christina Condon1,
- Marie Monbureau2,
- Mehrdad Shamloo2,
- Deqiang Jing3,
- Stephen M. Massa4, and
- Frank M. Longo1
- 1Department of Neurology and Neurological Sciences and
- 2Behavioral and Functional Neuroscience Laboratory, Institute for Neuro-Innovation and Translational Neurosciences, Stanford University School of Medicine, Stanford, California 94305,
- 3Department of Psychiatry, Weill Cornell Medical College, New York, New York 10021, and
- 4Department of Neurology and Laboratory for Computational Neurochemistry and Drug Discovery, Department of Veterans Affairs Medical Center and Department of Neurology, University of California, San Francisco, San Francisco, California 94121
Author contributions
Author contributions: D.A.S. and F.M.L. designed research; D.A.S., N.P.B., T.Y., M.M., and M.S. performed research; D.J. contributed unpublished reagents/analytic tools; D.A.S., N.P.B., and C.C. analyzed data; D.A.S., S.M.M., and F.M.L. wrote the paper.
Disclosures
- Received March 27, 2013.
- Revision received September 9, 2013.
- Accepted October 12, 2013.
This work was supported by the National Institutes of Health Grants R21 NS071024-01 and P30 NS069375-01A1, Taube Philanthropies, Koret Foundation, Jean Perkins Foundation, and the Veterans Administration.
F.M.L. is a founder of Pharmatrophix, a company focused on the development of neurotrophin receptor ligands.
- Correspondence should be addressed to Frank M. Longo, Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA 94305. longo{at}stanford.edu
